Log in

Start Your Membership Now

On August 16, 2016, the federal food and drug administration (FDA) granted breakthrough therapy designation to Johnson & Johnson subsidiary, Janssen Research & Development, for the company’s investigational antidepressant medication, esketamine. Esketamine was granted breakthrough therapy designation for the treatment of major depressive disorder with imminent risk for suicide. This is the second time esketamine has received breakthrough therapy designation, the drug received this distinction for treatment-resistant depression in November 2013.

This was reported by PharmTech.com on August 16, 2016.

Contact Information: Janssen Pharmaceuticals, Inc., 1125 Trenton-Harbourton Road, Post Office Box 200, Titusville, New Jersey 08560 . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
Log In
If you are already a member, log in to your account to access this resource and more.

Become A Free Member
You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

Service & Treatment Updates

Categories
All Bulletins
Submit a Bulletin
  • This field is for validation purposes and should be left unchanged.
  • Max. file size: 98 MB.